宮頸癌
宮頸癌是一種發(fā)生在女性生殖系統(tǒng)中宮頸部位的惡性腫瘤。宮頸癌的主要病因是人乳頭狀瘤病毒(HPV)感染,尤其是HPV的高危型別,如HPV 16和18型。其他相關(guān)的危險因素包括抽煙、多個性伴侶、性生活開始過早、多孕多產(chǎn)以及免疫功能缺陷等。宮頸癌的臨床表現(xiàn)隨著疾病的進展而變化,早期可能沒有癥狀,但隨著病情發(fā)展,可能出現(xiàn)接觸性出血、異常陰道流血等癥狀。
在宮頸癌的治療方面,根據(jù)癌癥的分期和患者的具體情況,常用的治療手段包括手術(shù)、放療、化療、靶向治療和免疫治療。手術(shù)通常適用于早期宮頸癌,而放療和化療則常用于中晚期宮頸癌的治療。靶向治療和免疫治療是近年來新興的治療方法,主要用于復(fù)發(fā)或晚期宮頸癌的治療。
宮頸癌藥物研發(fā)的目前多集中在以下幾個方向:
- 免疫檢查點抑制劑:PD1/L1抑制劑如帕博利珠單抗(PD-1抑制劑)已被美國FDA批準(zhǔn)用于化療期間或后疾病進展的復(fù)發(fā)性或轉(zhuǎn)移性宮頸癌的治療。此外,帕博利珠單抗聯(lián)合化療也被批準(zhǔn)用于腫瘤表達PD-L1的持續(xù)性、復(fù)發(fā)性或轉(zhuǎn)移性宮頸癌患者的一線治療。
- 抗體藥物偶聯(lián)物(ADCs):Tisotumab Vedotin(TV)是首個獲批治療宮頸癌的ADC藥物,用于在化療期間或化療后病情進展的復(fù)發(fā)性或轉(zhuǎn)移性宮頸癌患者。TV的宮頸癌二線治療的Ⅲ期innovaTV301試驗顯示,相比傳統(tǒng)化療,TV能顯著降低死亡風(fēng)險并改善患者的總生存期(OS)。
- 雙特異性抗體:國內(nèi)企業(yè)自主研發(fā)的靶向PD-1和CTLA-4的雙特異性抗體凱得寧單抗(Cadonilimab,AK104)已申請上市,用于復(fù)發(fā)或轉(zhuǎn)移性宮頸癌的治療,并獲得了優(yōu)先審評。
宮頸癌藥物靶點
- ALPP
- AXL
- CA9
- CCR8
- CD22
- CD226
- CD247
- CD274
- CEACAM5
- CEACAM6
- CSF2RA
- CSF3R
- CTLA4
- DRD4
- E6
- E7
- EGFR
- ENTPD1
- ERBB2
- ERBB3
- fapA
- FLT1
- FLT3
- FOLR1
- HAVCR2
- ICOS
- IGF1R
- IL12A
- IL12RB1
- IL15RA
- IL17A
- IL2
- IL2RA
- IL2RB
- IL2RG
- ITGB6
- LAG3
- LAIR1
- LILRB1
- LILRB2
- LILRB4
- MUC16
- NECTIN4
- NT5E
- NTN1
- PDCD1
- PTCRA
- STING1
- TACSTD2
- TF
- TGFB1
- TGFB2
- TIGIT
- TNFRSF1A
- TNFRSF1B
- TNFSF9
- TOP1
- VEGFA
宮頸癌藥物靶點相關(guān)產(chǎn)品推薦
● 靶點蛋白
CSB-MP619964HU1

Measured by its binding ability in a functional ELISA. Immobilized PD-1 at 2 μg/ml can bind Anti-PD-1 recombinant antibody, the EC50 of human PD-1 protein is 6.087-7.854 ng/ml.
CSB-MP006163HU1

Measured by its binding ability in a functional ELISA. Immobilized CD152 at 2 μg/ml can bind Anti-CD152 rabbit monoclonal antibody (CSB-RA213310A0HU), the EC50 of human CD152 protein is 27.14-34.82 ng/ml.
CSB-MP878942HU1

Measured by its binding ability in a functional ELISA. Immobilized PD-L1 at 2 μg/ml can bind Anti- PD-L1 mouse monoclonal antibody(CSB-MA878942A1m, antigen from E.coli), the EC50 of human PD-L1 protein is 1.252-1.653 ng/mL
CSB-MP007763HU

Measured by its binding ability in a functional ELISA. Immobilized HER2 at 2 μg/ml can bind Trastuzumab, the EC50 is 2.179-2.825 ng/ml.
CSB-MP675446HU

HFACS assay shows that Human TIGIT can bind to 293F cell overexpressing human CD155.
CSB-MP007479HU

Human EGF protein captured on COOH chip can bind Human EGFR protein, his and Myc tag (CSB-MP007479HU) with an affinity constant of 11.9nM as detected by LSPR Assay.
CSB-MP007765HU

Measured by its binding ability in a functional ELISA. Immobilized NRG1 (CSB-MP016077HU1(F6)) at 2 μg/ml can bind human ERBB3, the EC50 is 12.32-15.74 ng/ml.

Measured by its binding ability in a functional ELISA. Immobilized TFRC (CSB-MP3648HU)at 2μg/mL can bind Human TF,the EC50 is 58.72-77.84 ng/mL.
● 穩(wěn)定細胞株

CHOK1/Human CCR8 Stable Cell Line
CSB-SC004847HU2
Untransfected CHO-K1 cells (green line) and transfected Human CCR8 CHO-K1 stable cells (red line) were stained with anti-CCR8 antibody (CSB-RA004847A1HU) (2μg/1*106 cells), washed and then followed by FITC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.

CT26/Human CCR8 Stable Cell Line
CSB-SC004847HU3
Untransfected CT26 cells (green line) and transfected Human CCR8 CT26 Stable cells (red line) were stained with anti-CCR8 antibody (2μg/1*106 cells), washed and then followed by FITC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.

CHOK1/Mouse CCR8 Stable Cell Line
CSB-SC004847MO
Untransfected CHO-K1 cells (green line) and transfected Mouse CCR8 CHO-K1 Stable cells (red line) were stained with anti-Mouse CD198-PE antibody (2μg/1*106 cells) and analyzed with flow cytometry.
● 重組抗體
CSB-RA183247A0HU

Overlay Peak curve showing HepG2 cells surface stained with CSB-RA183247A0HU (red line) at 1:50.
CSB-RA004847A1HU

Untransfected HEK293T cells surface (green line) and transfected Human CCR8 HEK293T stable cells surface (red line) were stained with anti-CCR8 antibody (2μg/1*106 cells)。
CSB-RA005165MA3HU

Overlay Peak curve showing Hela cells surface stained with CSB-RA005165MA3HU (red line) at 1:100.
CSB-RA159341A0HU

Overlay histogram showing Jurkat cells stained with CSB-RA159341A0HU (red line) at 1:50.
產(chǎn)品名稱 | 貨號 | 靶點 | 反應(yīng)種屬 | 應(yīng)用范圍 |
---|---|---|---|---|
ALPP Recombinant Monoclonal Antibody | CSB-RA183247A0HU | ALPP | Human | ELISA, WB, IHC, FC |
CA9 Recombinant Monoclonal Antibody | CSB-RA614990A0HU | CA9 | Human | ELISA, IHC |
CCR8 Recombinant Monoclonal Antibody | CSB-RA004847A1HU | CCR8 | Human | FC |
CCR8 Recombinant Monoclonal Antibody | CSB-RA004847MA3HU | CCR8 | Human | FC |
CCR8 Recombinant Monoclonal Antibody | CSB-RA004847MA2HU | CCR8 | Human | FC |
CCR8 Recombinant Monoclonal Antibody | CSB-RA004847MA4HU | CCR8 | Human | FC |
CD22 Recombinant Monoclonal Antibody | CSB-RA962691A0HU | CD22 | Human | ELISA, IHC |
CD247 Recombinant Monoclonal Antibody | CSB-RA244537A0HU | CD247 | Human | ELISA, FC |
CD274 Recombinant Monoclonal Antibody | CSB-RA977797A0HU | CD274 | Human | ELISA, WB, IHC |
CD274 Recombinant Monoclonal Antibody | CSB-RA878942MA1HU | CD274 | Human | ELISA, IHC, FC |
CEACAM5 Recombinant Monoclonal Antibody | CSB-RA005165MA3HU | CEACAM5 | Human | ELISA, IF, FC |
CEACAM5 Recombinant Monoclonal Antibody | CSB-RA005165MA1HU | CEACAM5 | Human | ELISA |
CTLA4 Recombinant Monoclonal Antibody | CSB-RA213310A0HU | CTLA4 | Human | ELISA, IHC |
CTLA4 Recombinant Monoclonal Antibody | CSB-RA006163MA1HU | CTLA4 | Human, Mouse | ELISA, WB, IF, FC |
Phospho-EGFR (Y1092) Recombinant Monoclonal Antibody | CSB-RA007479A1092phHU | EGFR | Human | ELISA, WB |
Phospho-EGFR (Y1068) Recombinant Monoclonal Antibody | CSB-RA007479A1068phHU | EGFR | Human | ELISA, WB |
EGFR Recombinant Monoclonal Antibody | CSB-RA159341A0HU | EGFR | Human | ELISA, WB, IHC, IF, FC |
EGFR Recombinant Monoclonal Antibody | CSB-RA794061A0HU | EGFR | Human | ELISA, WB, IHC |
EGFR Recombinant Monoclonal Antibody | CSB-RA159341MA1HU | EGFR | Human | ELISA, IHC, FC |
ENTPD1 Recombinant Monoclonal Antibody | CSB-RA568544A0HU | ENTPD1 | Human | ELISA, FC |
ERBB2 Recombinant Monoclonal Antibody | CSB-RA260392A0HU | ERBB2 | Human | ELISA, IHC, IF |
ERBB2 Recombinant Monoclonal Antibody | CSB-RA007763MA1HU | ERBB2 | Human | ELISA |
Phospho-ERBB2 (Y1139) Recombinant Monoclonal Antibody | CSB-RA588766A0HU | ERBB2 | Human | ELISA, IHC, IF |
ERBB2 Recombinant Monoclonal Antibody | CSB-RA007763MA2HU | ERBB2 | Human | ELISA, IHC |
ERBB3 Recombinant Monoclonal Antibody | CSB-RA937008A0HU | ERBB3 | Human | ELISA, IF |
FLT1 Recombinant Monoclonal Antibody | CSB-RA940669A0HU | FLT1 | Human, Mouse | ELISA, WB, IHC, FC |
IGF1R Recombinant Monoclonal Antibody | CSB-RA011087MA1HU | IGF1R | Human | ELISA, FC |
IL17A Recombinant Monoclonal Antibody | CSB-RA624104MA1HU | IL17A | Human | ELISA |
IL2RA Recombinant Monoclonal Antibody | CSB-RA011649MA1HU | IL2RA | Human | ELISA, IF |
MUC16 Recombinant Monoclonal Antibody | CSB-RA941216A0HU | MUC16 | Human | ELISA, IHC |
MUC16 Recombinant Monoclonal Antibody | CSB-RA973154A0HU | MUC16 | Human | ELISA, IHC |
NECTIN4 Recombinant Monoclonal Antibody | CSB-RA822274A0HU | NECTIN4 | Human | ELISA |
NT5E Recombinant Monoclonal Antibody | CSB-RA978310A0HU | NT5E | Human | ELISA, IHC |
PDCD1 Recombinant Monoclonal Antibody | CSB-RA240597A0HU | PDCD1 | Human | ELISA, WB, IHC |
TOP1 Recombinant Monoclonal Antibody | CSB-RA792129A0HU | TOP1 | Human | ELISA, WB, IHC, FC, IP |